Triterpene 27-P-coumatyl-uronic acid (27-P-CAUA), an EGFR tyrosine kinase inhibitor (TKI) with a specific molecular structure, well inhibits two distinct phenotypes in human BC cells, MDA-MB-468 (EGFR+HER2+) and HCC -1806 (EGFR-HER2 +) 45. Here, ERBB2 is linked to breast cancer.